Biomarkers.

Background: Plasma biomarkers have emerged as a promising tool to detect the presence of Alzheimer's disease (AD) when cognitive symptoms have not yet emerged. However, there is also a pressing need to detect and track subtle cognitive change at the preclinical stage of AD for population screening purposes and to monitor disease progression at scale. A potential solution is remote cognitive assessment, yet it is still not extensively employed.

Technology and Dementia Preconference.

Background: Plasma biomarkers have emerged as a promising tool to detect the presence of Alzheimer's disease (AD) when cognitive symptoms have not yet emerged. However, there is also a pressing need to detect and track subtle cognitive change at the preclinical stage of AD for population screening purposes and to monitor disease progression at scale. A potential solution is remote cognitive assessment, yet it is still not extensively employed.

Reliability generalization meta-analysis of the internal consistency of the Big Five Inventory (BFI) by comparing BFI (44 items) and BFI-2 (60 items) versions controlling for age, sex, language factors.

Introduction: The Big Five Inventory (BFI) is a popular measure that evaluates personality on the Big-Five model. Apart from its utilization across cultures, the literature did not reveal any meta-analysis for the reliability of the different versions of the BFI and its translations. The current study carried out a reliability generalization meta-analysis (REGEMA) to establish the reliability of the BFI across cultures and languages.

Correction: Impact of samarium on magnetic and optoelectronic properties of magnesium-based MgSm2X4 (X = S and Se) spinels for spintronics.

[This corrects the article DOI: 10.1371/journal.pone.

Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology.

This article updates the prior 2018 consensus statement by the National Network of Depression Centers (NNDC) on the use of transcranial magnetic stimulation (TMS) in the treatment of depression, incorporating recent research and clinical developments. Publications on TMS and depression between September 2016 and April 2024 were identified using methods informed by PRISMA guidelines. The NNDC Neuromodulation Work Group met monthly between October 2022 and April 2024 to define important clinical topics and review pertinent literature.